Holding(s) in Company

RNS Number:2403F
Cambridge Antibody Tech Group PLC
27 June 2006

                   NOTIFICATION OF MAJOR INTERESTS IN SHARES



1. Name of company


CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC



2. Name of shareholder having a major interest


DEUTSCHE BANK AG



3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18


DEUTSCHE BANK AG                   NOT NOTIFIED


4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them


DEUTSCHE BANK AG                   NOT DISCLOSED


5. Number of shares / amount of stock acquired


NOT DISCLOSED



6. Percentage of issued class



N/A



7. Number of shares / amount of stock disposed



NOT DISCLOSED



8. Percentage of issued class



N/A



9. Class of security



ORDINARY 10 PENCE SHARES



10. Date of transaction



NOT DISCLOSED

11. Date company informed



27 JUNE 2006



12. Total holding following this notification



NOT DISCLOSED



13. Total percentage holding of issued class following this notification



NOT KNOWN



14. Any additional information



DEUTSCHE BANK AG AND ITS SUBSIDIARY COMPANIES NO LONGER HAVE A NOTIFIABLE
INTEREST IN THE ORDINARY SHARES OF CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC.



15. Name of contact and telephone number for queries



JUSTIN HOSKINS 01223 898589



16. Name and signature of authorised company official responsible for making
this notification



JUSTIN HOSKINS, COMPANY SECRETARY



Date of notification



27 JUNE 2006



The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

HOLEALKXAALKEFE